Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-040128
Filing Date
2020-08-14
Accepted
2020-08-13 19:38:19
Documents
49
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvus-10q_20200630.htm 10-Q 1683274
2 EX-31.1 nvus-ex311_7.htm EX-31.1 11348
3 EX-31.2 nvus-ex312_6.htm EX-31.2 11491
4 EX-32.1 nvus-ex321_8.htm EX-32.1 7484
5 EX-32.2 nvus-ex322_9.htm EX-32.2 7862
  Complete submission text file 0001564590-20-040128.txt   4825555

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nvus-20200630.xml EX-101.INS 842934
7 XBRL TAXONOMY EXTENSION SCHEMA nvus-20200630.xsd EX-101.SCH 43193
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nvus-20200630_cal.xml EX-101.CAL 31257
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nvus-20200630_def.xml EX-101.DEF 86841
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvus-20200630_lab.xml EX-101.LAB 272867
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvus-20200630_pre.xml EX-101.PRE 194248
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36620 | Film No.: 201100866
SIC: 2834 Pharmaceutical Preparations